Zusammenfassung
Antiparkinsonmittel sind Arzneimittel zur Behandlung der Symptome des Morbus Parkinson. Antiparkinsonmittel im engeren Sinne zielen auf die im Vordergrund stehenden motorischen Symptome (Akinese, Rigor, Tremor) und werden hier im Detail beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Weiterführende Literatur
Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 8(10):929–937
Charvin D, Medori R, Hauser RA, Rascol O (2018) Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 17(11):804–822
Lewitt PA (2009) MAO-B inhibitor know-how: back to the pharm. Neurology 72(15):1352–1357
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912
Möller JC, Körner Y, Dodel RC, Meindorfner C, Stiasny-Kolster K, Spottke A, Krüger HP, Oertel WH (2005) Pharmacotherapy of Parkinson’s disease in Germany. J Neurol 252(8):926–935
Schapira AH (2009) Neurobiology and treatment of Parkinson’s disease. Trends Pharmacol Sci 30(1):41–47
Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Böhm, S. (2020). Antiparkinsonmittel. In: Pharmakologie und Toxikologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58304-3_34
Download citation
DOI: https://doi.org/10.1007/978-3-662-58304-3_34
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-58303-6
Online ISBN: 978-3-662-58304-3
eBook Packages: Medicine (German Language)